U.S. Markets closed

Veloxis Increases Share Capital in Connection with Exercise of Warrants

Company Release no. 15/2019

To: NASDAQ Copenhagen A/S                                                      

Copenhagen, Denmark, 05 September 2019


Veloxis Increases Share Capital in Connection with Exercise of Warrants


Veloxis Pharmaceuticals A/S announces that the Company's capital has been increased by 2,015,200 new shares with a nominal value of DKK 0.10 each corresponding to nominally DKK 201,520 as a consequence of the exercise of warrants by current and former employees of the Company granted under the Company's warrant program.

As a result of the employee’s investment in the Company proceeds to Veloxis Pharmaceuticals A/S from the capital increase amount to DKK 2,138,300.40.

The subscription price for the new shares is DKK 0.35 per share of nominal DKK 0.10 (with regard to 61,700 shares), DKK 0.86 per share of nominal DKK 0.10 (with regard to 220,832 shares), DKK 0.94 per share of nominal DKK 0.10 (with regard to 8,315 shares), DKK 0.95 per share of nominal DKK 0.10 (with regard to 508,303 shares), DKK 1.01 per share of nominal DKK 0.10 (with regard to 615,553 shares), DKK 1.06 per share of nominal DKK 0.10 (with regard to 50,000 shares), DKK 1.12 per share of nominal DKK 0.10 (with regard to 281,943 shares), DKK 1.24 per share of nominal DKK 0.10 (with regard to 100,000 shares), DKK 1.32 per share of nominal DKK 0.10 (with regard to 13,000 shares), DKK 1.86 per share of nominal DKK 0.10 (with regard to 80,000 shares), DKK 2.06 per share of nominal DKK 0.10 (with regard to 75,554 shares).

The new shares will be listed on NASDAQ Copenhagen following registration of the capital increase with the Danish Business Authority, upon which the share capital of Veloxis Pharmaceuticals A/S will be DKK 173,833,081.70 divided into shares of DKK 0.10 each.

Each share of nominal DKK 0.10 carries one vote at general meetings in Veloxis Pharmaceuticals A/S.  The new shares give rights to dividend and other rights from the time of registration of the capital increase with the Danish Business Authority.


For more information, please contact:

 Craig A. Collard      Ira Duarte
 President & CEO    CFO
 Phone: + 1 919 591 3090    Phone: +1 919 591 3090
 Email: cac@veloxis.com    Email: idu@veloxis.com


             

About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals, Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA.  Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the Company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs.  The Company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  For further information, please visit www.veloxis.com.


Attachment